University of Pennsylvania

ScholarlyCommons
Botswana-UPenn Scholarly Publications

Botswana-UPenn Partnership

9-11-2013

Risk Factors for Suboptimal Antiretroviral Therapy Adherence in
HIV-Infected Adolescents in Gaborone, Botswana: A Pilot CrossSectional Study
Maimouna Ndiaye
Peter Nyasulu
Hoang Nguyen
Elizabeth D. Lowenthal
University of Pennsylvania, lowenthale@email.chop.edu

Robert Gross
University of Pennsylvania, grossr@mail.med.upenn.edu

See next page for additional authors

Follow this and additional works at: https://repository.upenn.edu/botswana_schol
Part of the Immune System Diseases Commons

Recommended Citation
Ndiaye, Maimouna; Nyasulu, Peter; Nguyen, Hoang; Lowenthal, Elizabeth D.; Gross, Robert; Mills, Edward
J.; and Nachega, Jean B., "Risk Factors for Suboptimal Antiretroviral Therapy Adherence in HIV-Infected
Adolescents in Gaborone, Botswana: A Pilot Cross-Sectional Study" (2013). Botswana-UPenn Scholarly
Publications. 8.
https://repository.upenn.edu/botswana_schol/8

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/botswana_schol/8
For more information, please contact repository@pobox.upenn.edu.

Risk Factors for Suboptimal Antiretroviral Therapy Adherence in HIV-Infected
Adolescents in Gaborone, Botswana: A Pilot Cross-Sectional Study
Abstract
Objective: Little is known about factors associated with suboptimal antiretroviral treatment (ART)
adherence among adolescents in Sub-Saharan Africa. Our objective was to determine the level of ART
adherence and predictors of non-adherence among human immunodeficiency virus (HIV)-infected
adolescents at the Botswana-Baylor Children's Clinical Centre of Excellence in Gaborone, Botswana.
Methods: In a cross-sectional study, 82 HIV-infected adolescents receiving ART and their caregivers were
administered a structured questionnaire. The patient's clinical information was retrieved from medical
records. Outcome measures included excellent pill count ART adherence (>95%) and virologic
suppression (HIV viral load <400 copies>/mL). Multivariate logistic regression analysis was performed to
identify independent predictors of ART non-adherence.
Results: The overall median (interquartile range) ART adherence was 99% (96.5–100) (N = 82). Seventysix percent of adolescents had excellent pill count ART adherence levels and 94% achieved virologic
suppression. Male adolescents made up 65% of the non-adherent group (P = 0.02). Those who displayed
suboptimal ART adherence were more likely to report having ever missed ART doses due to failure to pick
up medication at the pharmacy (30.0% versus 9.7%, P = 0.03). In the multivariate logistic regression
model, male sex (odds ratio [OR] 3.29, 95% confidence interval [CI] 1.13–9.54; P = 0.03) was the only
factor which was independently associated with suboptimal ART adherence.
Conclusions: A high proportion of HIV-infected adolescents studied had excellent ART adherence and
virologic suppression, with male adolescents at higher risk of suboptimal adherence than females.
Further research to investigate how gender relates to suboptimal adherence may aid in the design of
targeted intervention strategies.
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Objective: Little is known about factors associated with suboptimal antiretroviral treatment
(ART) adherence among adolescents in Sub-Saharan Africa. Our objective was to determine
the level of ART adherence and predictors of non-adherence among human immunodeficiency
virus (HIV)-infected adolescents at the Botswana-Baylor Children’s Clinical Centre of Excellence in Gaborone, Botswana.
Methods: In a cross-sectional study, 82 HIV-infected adolescents receiving ART and their
caregivers were administered a structured questionnaire. The patient’s clinical information was
retrieved from medical records. Outcome measures included excellent pill count ART adherence (.95%) and virologic suppression (HIV viral load ,400 copies/mL). Multivariate logistic
regression analysis was performed to identify independent predictors of ART non-adherence.
Results: The overall median (interquartile range) ART adherence was 99% (96.5–100) (N = 82).
Seventy-six percent of adolescents had excellent pill count ART adherence levels and 94%
achieved virologic suppression. Male adolescents made up 65% of the non-adherent group
(P = 0.02). Those who displayed suboptimal ART adherence were more likely to report having
ever missed ART doses due to failure to pick up medication at the pharmacy (30.0% versus
9.7%, P = 0.03). In the multivariate logistic regression model, male sex (odds ratio [OR] 3.29,
95% confidence interval [CI] 1.13–9.54; P = 0.03) was the only factor which was independently
associated with suboptimal ART adherence.
Conclusions: A high proportion of HIV-infected adolescents studied had excellent ART adherence and virologic suppression, with male adolescents at higher risk of suboptimal adherence
than females. Further research to investigate how sex relates to suboptimal adherence may aid
in the design of targeted intervention strategies.
Keywords: HIV/AIDS, ART adherence, adolescents, barriers, Botswana

Introduction
In 2011, an estimated 330,000 children under the age of 15 years were newly infected
with human immunodeficiency virus (HIV), contributing to an estimated 3.3 million
children living with HIV worldwide. Over 90% of these children live in Sub-Saharan
Africa and less than a third of them have access to antiretroviral treatment (ART).1 In
2009 in Botswana, 19,125 children aged 0–14 years were living with HIV infection.2,3
Access to ART has significantly reduced mortality among children with HIV. However,
children and adolescents experience unique challenges to sustained treatment adherence,
including the need for support from caregivers and providers, issues surrounding the disclosure of HIV status, their rebellious nature, and management of adverse events.4–13
The few available data from sub-Saharan Africa have shown that, compared with
adults, adolescents were less adherent to ART, had lower rates of virologic suppression,
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and had a higher rate of virologic rebound after initial suppression.9–12 However, specific data on possible barriers for
poor ART adherence were not reported. The objective of the
present study, therefore, was to investigate ART adherence
and the factors associated with suboptimal adherence among
HIV-infected adolescents at the Botswana-Baylor Children’s
Clinical Centre of Excellence (BBCCCOE).

Methods
We conducted a cross-sectional study of HIV-infected
adolescents between August 2010 and March 2011 at the
BBCCCOE in Gaborone, Botswana. BBCCCOE is a comprehensive HIV/AIDS treatment care center based at Princess
Marina Hospital, the main referral hospital in Gaborone. At
this clinical setting, informal one-on-one adherence education
and counseling is provided to all patients during routine care.
Patients and families found to have adherence challenges are
given intensified counseling with the head nurse, clinical
psychologist, or social worker. A support group is available
for adolescents who are at least 13 years of age and who
know their HIV status. Using purposive sampling, adolescents aged 13 to 18 years of age who had been on ART for
a period longer than 6 months were eligible to participate in
the study. The cut-off point of 6 months was chosen to allow
us to use viral load as an endpoint, because it can take up to
6 months for individuals to achieve virologic suppression
on ART.14 Because all study subjects were minors, consent
from parents/guardians was required along with participant
assent.15
A standardized self-administered questionnaire adapted
from the AIDS Clinical Trials Group16 was used to collect
socio-demographic information as well as other explanatory variables (HIV status of caregivers, the adolescent’s
relationship with caregivers, and the presence or absence
of a family and friend network support, among others).
In addition, electronic medical record system was used to
retrieve clinical and laboratory data. Pill count data were
used to assess adherence to ART over the previous month,
as medication is dispensed on a monthly basis. The proportion of adherence was calculated as follows: the numerator
was the total number of pills provided at the previous visit
minus the number of pills remaining, and the denominator
was the number of pills required per day times the number
of days since the last visit; this ratio was multiplied by 100.
Adherence to ART was considered excellent when the pill
count was $95% of prescribed doses.17
Sociodemographic and clinical characteristics of the
participants as well as adherence rates were compared using
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Chi-square or Fisher’s exact test for categorical variables.
Wilcoxon’s rank-sum test was used for continuous variables.
Logistic regression was performed to identify factors associated with adherence. Variables in the univariate analysis
with a P , 0.1, as well as selected factors hypothesized to
be confounding factors (a factor associated with the predictor and outcome but not in the causal path), such as age
above the median, CD4+ T-cell count, and World Health
Organisation (WHO) clinical stage, were included in the
multivariate logistic regression model. All P-values reported
are two-tailed. A P-value ,0.05 was considered significant.
Data were entered in Epi Info 2003 (US Centers for Disease
Control, Atlanta, GA, USA) and analyzed using Statistical
Package STATA release 11.2 (STATA Corporation, College
Station, TX, USA).
Ethical approvals were obtained from the following ethical review committees: the Health Research and
Development Division, Ministry of Health, Botswana;
the Human Research Ethics Committee, University of the
Witwatersrand, Johannesburg, South Africa; and the Institutional Review Board for Human Subject Research, Baylor
College of Medicine, Houston, TX, USA.

Results
Of 400 adolescents informed about the study, only 82 consented
and enrolled. The most prevalent (.90%) reasons for not
enrolling in the study were nonavailability of a caregiver at the
clinic and lack of interest. 40.2% of the adolescents were on
a non-nucleoside reverse transcriptase (NNRTI, efavirenz or
nevirapine)-based ART regimen and 58.5% were on a protease
inhibitor (lopinavir-boosted ritonavir (LPV/r))-based ART regimen. But only 13 of 82 (16%) adolescents in this study were
on a second-line ART regimen ([LPV/r-based ART: n = 12]
or [raltegravir-based ART: n = 1]). The main demographics,
clinical and laboratory data, as well as factors for nonadherence documented at enrollment, are shown in Table 1. Overall,
75.6% of adolescents had excellent (.95%) pill count ART
adherence levels, and all but 5 (94%) had virologic suppression
to less than 400 copies/mL. Male adolescents made up 65% of
the non-adherent group, but only 35.5% of the adherent group
(P = 0.02). Study participants who self-reported suboptimal
ART adherence were more likely to report having ever missed
ART doses due to failure to pick up medication at the pharmacy
(30.0% versus 9.7%, P = 0.03). In univariate analysis, male sex
(odds ratio [OR] 3.38, 95% confidence interval [CI] 1.17–9.71;
P = 0.02) and failure to refill ART medicine at the pharmacy
(OR 4.31, 95% CI 1.19–15.53; P = 0.03) were significantly
associated with suboptimal ART adherence. In the multivariate
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Table 1 Clinical and socio-demographics at enrolment by pill count ART adherence threshold of 95%
Variables

Number
(N = 82)

Adherent ($95%)
(62, 75.6%)

Nonadherent (,95%)
(20, 24.4%)

P- value

Age, median (IQR)
Male sex, n (%)
WHO Stage, n (%)
 I
 II
 III
 IV
CD4 T-cell count, median (IQR)
Viral load ,400 copies/mL, n (%)
Duration on ART in years, median (IQR)
Duration on ART .5 years, n (%)
ART regiment, n (%)
 NNRTI-based
PI-based
 Other
Female caregiver, n (%)
Biologic relation with caregiver, n (%)
Caregiver HIV status known, n (%)
Caregiver with HIV+, n (%)
Family support network, n (%)
 Do you discuss with parents/caregiver about
the importance of adherence to ART? (yes)
Perception (outcome expectancy), n (%)
 Do you believe the pills you are taking are
going to make you a healthy person? (yes)
Drug toxicity, n (%)
Do you feel fine after taking your pills? (yes)
Pharmacy no refill, n (%)
 Have you ever missed a dose because
you, your parents or caregiver did not
collect the pills at the pharmacy? (yes)

15 (14–16)
35 (42.7)

15 (14–16)
22 (35.5)

15 (14–16)
13 (65.0)

0.43
0.02
0.42

12 (14.6)
11 (13.4)
34 (41.5)
25 (30.5)
759 (575–946)
77 (93.9)
5 (3–6)
37 (45.1)

9 (14.5)
9 (14.5)
28 (45.2)
16 (25.8)
746 (528–1011)
59 (95.2)
5 (3–6)
27 (43.5)

3 (15.0)
2 (10.0)
6 (30.0)
9 (45.0)
779 (628–886)
18 (90.0)
5 (3–6)
10 (50.0)

33 (40.2)
48 (58.5)
1 (1.3)
73 (90.1)
45 (55.6)
52 (64.2)
36 (73.5)

24 (38.7)
37 (59.7)
1 (1.6)
55 (88.7)
35 (56.4)
39 (62.9)
27 (71.0)

9 (45.0)
11 (55.0)
0 (0.0)
18 (94.7)
10 (52.6)
13 (68.4)
9 (81.8)

0.67
0.80
0.79
0.70

63 (76.8)

48 (77.4)

15 (75.0)

0.82

75 (91.5)

57 (91.9)

18 (90.0)

0.79

75 (91.5)

57 (91.9)

18 (90.0)

0.79

12 (14.8)

6 (9.7)

6 (30.0)

0.03

0.70
0.59
0.96
0.80
0.84

Abbreviations: IQR, interquartile range; ART, antiretroviral treatment; WHO, World Health Organisation; NNRTI, non-nucleoside reverse transcriptase; PI, protease
inhibitor; HIV, human immunodeficiency virus.

analysis, male sex (OR 3.29, 95% CI 1.13–9.54; P = 0.03)
was the only factor which was independently and significantly
associated with suboptimal ART adherence (Table 2).

Discussion
This study found that 75.6% of adolescents with a median
ART duration of 5 years had excellent (.95%) ART adherence, with an overall mean of 96.4%. These findings are
important because there is emerging concern that there are
specific challenges for adolescent patients, such as rebelliousness and potentially higher rates of mortality, when
compared to other populations.18
Although some studies have shown similar high rates of
ART adherence among HIV-infected adolescents,6 a lower
rate of adherence among HIV-infected adolescents has been
reported more often,5–7,9 and expectations have been that adherence will diminish over time. In 2009, a review of studies on
ART adherence and intervention among HIV-infected youths
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(13–24 years old) reported an overall rate of adherence ranging
from 28.3% to 69.8%.6 The high proportion of HIV-infected
adolescents with excellent pill count ART adherence and
virologic suppression documented in our study is encouraging
and demonstrates that excellent treatment outcomes can be
achieved in HIV-infected adolescents in this setting. Interestingly, analysis of the barriers to adherence in this study revealed
that male sex was an independent predictor of nonadherence to
ART in our cohort. Our data are supported by a study of 804
children and adolescents between the ages of 3 and 16 years at
initiation on NNRTI-based treatment at the same clinical site
by Lowenthal et al,19 who reported that patients of both sexes
were more likely to have had virologic failure on nevirapinebased treatment than on efavirenz-based treatment, but failure
rates on both regimens were higher among males than among
females, with males on nevirapine having the highest failure
rates. The findings of our study suggest that the sex-specific
differences in outcomes observed by Lowenthal et al may be
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Table 2 Univariate and multivariate logistic regression model of factors associated with ART adherence ,95%
Univariate
Age above median
Male sex
WHO stage III and IV (versus I and II)
PI-based versus NNRTI-based regimen
CD4 above median
VL ,400 copies/mL
Biologic relation with caregiver
Caregiver who is HIV+
Caregiver with HIV status known
Having a support network
Positive outcome expectancy
Never experience ART side
effects/toxicity

Multivariate

OR (95% CI)

P-value

OR (95% CI)

P-value

0.73 (0.24–2.15)
3.38 (1.17–9.71)
1.23 (0.39–3.88)
0.79 (0.28–2.20)
1.30 (0.47–3.59)
0.46 (0.07–2.95)
0.86 (0.30–2.40)
1.83 (0.34–9.88)
1.28 (0.43–3.82)
0.87 (0.27–2.83)
0.79 (0.14–4.42)
0.79 (0.14–4.42)

0.56
0.02
0.73
0.65
0.61
0.40
0.77
0.48
0.66
0.82
0.79
0.79

0.87 (0.27–2.77)
3.29 (1.13–9.54)
1.02 (0.30–3.47)

0.81
0.03
0.97

1.18 (0.40–3.44)

0.76

Abbreviations: PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase; VL, viral load; ART, antiretroviral treatment; WHO, World
Health Organisation; CI, confidence interval; OR, odds ratio; HIV, human immunodeficiency virus.

explained by worse adherence in males. Furthermore, there
is a growing body of evidence indicating that adult men face
important challenges in accessing HIV services as often as
their female counterparts and also experience worse treatment
outcomes, including mortality.18,20,21
The fact that patients fail to pick up ART medications at
the pharmacy at all suggests that structural barriers (eg, lack
of transport money to access the clinic or other factors)22,23
may play a role in this study population. In addition, because
even one incidence of not obtaining a refill on time is strongly
associated with current pill count adherence suggests that
there are long-term concerns (forgetfulness, not making their
medicines a priority, chaotic households, and so forth) for
those who ever miss a refill date. Essentially, if a patient has
ever missed a refill, he or she is more likely to miss doses
now, suggesting a long-term increased risk of suboptimal
adherence even in the absence of ongoing refill problems.
Although our results are informative and preliminary and
need further confirmatory studies, they suggest that male
adolescents, and those having a history of ever failing to refill
ART at the pharmacy in this setting, may benefit from more
intensive monitoring and adherence interventions.24
Our study may be limited by selection bias and findings
may not be generalizable to other settings in Africa. The BBCCCOE site has better resources than many clinics in resourcelimited settings, including a supportive environment that aims
to equip teenagers with the appropriate skills to enable them
to face the challenges of adolescence; this may in part explain
the documented high ART adherence here. Furthermore, we
recruited from among patients with an available caregiver at
the clinic. Those who did not have an available caregiver, as
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well as those not able to consent due to lack of interest or
other reasons, were less likely to be included but may have
been poorly adherent to their ART regimen.

Conclusions
This study found that a high proportion of HIV-infected adolescents aged 13 to 18 years who are attending the BBCCCOE
for HIV care are highly adherent to their ART medication
regimens and achieved virologic suppression. Being male and
having a history of failure to refill ART at a pharmacy were
significant risk factors for suboptimal adherence among HIV/
AIDS-infected adolescents in this study population. Our data
call for a prospective evaluation in a larger study to confirm
our findings and investigate further why males are more likely
to have suboptimal adherence than females; this may improve
the design of targeted intervention strategies in this setting.
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